Effect of alpha linolenic acid on cardiovascular risk markers: a systematic review - PubMed (original) (raw)

Review

Effect of alpha linolenic acid on cardiovascular risk markers: a systematic review

E Wendland et al. Heart. 2006 Feb.

Abstract

Objective: To determine whether dietary supplementation with alpha linolenic acid (ALA) can modify established and emerging cardiovascular risk markers.

Design: Systematic review and meta-analysis of randomised controlled trials identified by a search of Medline, Embase, Cochrane Controlled Trials Register (CENTRAL), and the metaRegister of Controlled Trials (mRCT).

Patients: All human studies were reviewed.

Main outcome measures: Changes in concentrations of total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, triglyceride, fibrinogen, and fasting plasma glucose, and changes in body mass index, weight, and systolic and diastolic blood pressure.

Results: 14 studies with minimum treatment duration of four weeks were reviewed. ALA had a significant effect on three of the 32 outcomes examined in these studies. Concentrations of fibrinogen (0.17 micromol/l, 95% confidence interval (CI) -0.30 to -0.04, p = 0.01) and fasting plasma glucose (0.20 mmol/l, 95% CI -0.30 to -0.10, p < 0.01) were reduced. There was a small but clinically unimportant decrease in HDL (0.01 mmol/l, 95% CI -0.02 to 0.00, p < 0.01). Treatment with ALA did not significantly modify total cholesterol, triglycerides, weight, body mass index, LDL, diastolic blood pressure, systolic blood pressure, VLDL, and apolipoprotein B.

Conclusions: Although ALA supplementation may cause small decreases in fibrinogen concentrations and fasting plasma glucose, most cardiovascular risk markers do not appear to be affected. Further trials are needed, but dietary supplementation with ALA to reduce cardiovascular disease cannot be recommended.

PubMed Disclaimer

Figures

None

Similar articles

Cited by

References

    1. Bucher H C, Hengstler P, Schindler C.et al N‐3 polyunsaturated fatty acids in coronary heart disease: a meta‐analysis of randomized controlled trials. Am J Med 2002112298–304. - PubMed
    1. Gerster H. Can adults adequately convert alpha‐linolenic acid (18:3n‐3) to eicosapentaenoic acid (20:5n‐3) and docosahexaenoic acid (22:6n‐3)? Int J Vitam Nutr Res 199868159–173. - PubMed
    1. De Lorgeril M, Salen P, Martin J L.et al Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon diet heart study. Circulation 199999779–785. - PubMed
    1. Bemelmans W J, Broer J, Feskens E J.et al Effect of an increased intake of alpha‐linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean alpha‐linolenic enriched Groningen dietary intervention (MARGARIN) study. Am J Clin Nutr 200275221–227. - PubMed
    1. Finnegan Y E, Minihane A M, Leigh Firbank E C.et al Plant‐ and marine‐derived n‐3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. Am J Clin Nutr 200377783–795. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources